Get the Stockscreener App
2.47
0.82%
0.02
Pre-market:
2.67
0.20
+8.10%
Jyong Biotech Ltd stock is traded at $2.47, with a volume of 124.63K.
It is up +0.82% in the last 24 hours and up +14.35% over the past month.
Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates.
See More
Previous Close:
$2.45
Open:
$2.48
24h Volume:
124.63K
Relative Volume:
0.30
Market Cap:
$183.36M
Revenue:
-
Net Income/Loss:
$-2.95M
P/E Ratio:
-61.44
EPS:
-0.0402
Net Cash Flow:
-
1W Performance:
+30.00%
1M Performance:
+14.35%
6M Performance:
-95.25%
1Y Performance:
+0.00%
1-Day Range:
$2.41
$2.68
1-Week Range:
$1.88
$2.68
52-Week Range:
$1.43
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Compare MENS vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
2.47 | 181.87M | 0 | -2.95M | 0 | -0.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 110.47B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.67B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 43.81B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.36B | 606.42M | -1.28B | -997.58M | -6.403 |
Jyong Biotech Ltd Stock (MENS) Latest News
MENS PE Ratio & Valuation, Is MENS Overvalued - Intellectia AI
Director of Jyong Biotech (MENS) files Form 3 showing 3,000 common shares - Stock Titan
Director Hsu Feng-Lin reports 3,000 Jyong Biotech (MENS) shares on Form 3 - Stock Titan
Director at Jyong Biotech (MENS) discloses holding 3,000 shares - Stock Titan
Jyong Biotech (MENS) director Fan Hung-Shu files initial Form 3 - Stock Titan
Jyong Biotech (MENS) director files Form 3 with no insider trades - Stock Titan
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 22.7% in March - Defense World
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2 - Bitget
A plant-based prostate drug finished Phase III trials in the U.S. and Taiwan - Stock Titan
MENS Stock Price, Quote & Chart | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
Jyong Biotech Ltd PE Ratio (TTM) & PE Ratio (TTM) ChartsMENS - GuruFocus
Chinese firm sues Taiwan’s Jyong Biotech Ltd. in Cayman to enforce ¥152M China judgment - OffshoreAlert
Jyong Biotech Ltd. (NASDAQ:MENS) Sees Large Decrease in Short Interest - MarketBeat
Jyong Biotech 'not aware' of any material information amid share price movement - MSN
MENS Earnings History & Surprises | EPS & Revenue Results | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
MENS Should I Buy - Intellectia AI
Jyong Biotech (NASDAQ:MENS) Stock Price Down 12.3%Time to Sell? - MarketBeat
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia - The Manila Times
MENS Technical Analysis & Stock Price Forecast - Intellectia AI
Prostate cancer therapy also lowers cholesterol in 2-year trial - Stock Titan
CEO Fu-Feng Kuo, Jyong Biotech Ltd.'s (NASDAQ:MENS) largest shareholder sees value of holdings go down 23% after recent drop - Yahoo Finance
Jyong Biotech appoints Wei (Vivi) Zhang as chief financial officer By Investing.com - Investing.com India
Jyong Biotech appoints Wei (Vivi) Zhang as chief financial officer - Investing.com Nigeria
Jyong Biotech Appoints Veteran Capital Markets Executive Wei Zhang as Chief Financial Officer - TipRanks
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Update - MarketBeat
Jyong Biotech subsidiary announces phase II data for MCS-8 - TipRanks
Jyong Biotech reports positive results from MCS-8 phase II trial - Investing.com
Prostate cancer trial drug also improves cholesterol in 2-year study - stocktitan.net
Jyong Biotech Reports Higher Assets but Deeper Shareholders’ Deficit in June 2025 Unaudited Results - TipRanks
Jyong Biotech Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 - MarketScreener
FLYEXCLUSIVE INC. (FLYX) Stock, Price, News, Quotes, Forecast and Insights - MSN
Axsome Therapeutics, Plug Power And Other Big Stocks Moving Higher On Wednesday - Benzinga
After the recent decline, Jyong Biotech Ltd. (NASDAQ:MENS) CEO Fu-Feng Kuo's holdings have lost 33% of their value - simplywall.st
Sidus Space, Starfighters Space And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Jyong Biotech (NASDAQ:MENS) Shares Gap UpStill a Buy? - MarketBeat
Jyong Biotech Ltd.(NasdaqGM: MENS) added to NASDAQ Biotechnology Index - marketscreener.com
Jyong Biotech addresses share price fluctuations amid lock-up expiry By Investing.com - Investing.com Nigeria
Jyong Biotech in Talks With Funds Interested in Buying Shares - marketscreener.com
Jyong Biotech addresses share price fluctuations amid lock-up expiry - Investing.com
Jyong Biotech in talks with investment funds for purchasing co's ordinary shares - marketscreener.com
Jyong Biotech ‘not aware’ of any material information amid share price movement - TipRanks
Jyong Biotech Responds to Share Price and Volume Movement - The Manila Times
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Jyong Biotech Ltd Stock (MENS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):